Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Congestive Heart Failure
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Congestive Heart Failure
    TopAbstracts in Congestive Heart Failure 11/26/2009 - (DGNews)
    Administering Epinephrine During Cardiac Arrest Does Not Appear to Improve Long-Term Survival - (DGNews)
    Continuous-Flow Heart Pump Improves Survival Better Than Pulsatile Type for Patients With Advanced Heart Failure: Presented at AHA - (DGDispatch)
    FDA Investigates Risk of Cardiovascular Events in Patients Using Sibutramine - (DGNews)
    Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency - (N Engl J Med)

    News archive

     Recent webcasts/CME - Congestive Heart Failure
    • What Clinicians Need To Know About Antiplatelet Therapy and Managing Acute Coronary Syndrome: A Roundtable Discussion
    • And the Survey Says: What Do Clinicians Need To Know About Managing Their Patients With ACS?
    • Optimal Duration and Risks of Antiplatelet Therapy: What Have We Learned?
    • Emerging Trends in the Management of Arrhythmias and Pump Failure in Patients with Advanced HF
      Future Direction of Stem Cells in Cardiovascular Disease

      Webcasts/CME archive

       Recent cases - Congestive Heart Failure
        Congestive Heart Failure
        Spontaneous Left Main Coronary Artery Dissection Complicated by Pseudoaneurysm Formation in Pregnancy: Role of CT Coronary Angiography
        Cardiogenic Shock as a Complication of Acute Mitral Valve Regurgitation Following Posteromedial Papillary Muscle Infarction in the Absence of Coronary Artery Disease
        Hyperthyroidism as a Reversible Cause of Right Ventricular Overload and Congestive Heart Failure
        Congestive Cardiac Failure and Anemia in a 15-Year-Old Boy

        Cases archive
          




        my personal edition > congestive heart failure > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Sildenafil May Yield Modest Benefits in Systolic Heart Failure: Presented at HFSA

        By Bonnie Darves

        SEATTLE, WA -- September 18, 2006 -- A new study of sildenafil, a drug commonly prescribed for erectile dysfunction and pulmonary arterial hypertension, has found that the medication may also improve exercise capacity and quality of life while reducing heart failure (HF)-associated hospitalizations in patients with systolic HF.

        In a randomized, placebo-controlled study, patients who received sildenafil were able to improve their 6-minute walk distance by 13% -- a modest but notable gain for patients with Class III or IV systolic HF, according to the study's chief author, Gregory D. Lewis, MD, researcher, Massachusetts General Hospital, Boston, Massachusetts.

        Researchers plan to look further at the data to determine whether sildenafil "has peripheral effects, such as improving endothelial function" in HF patients, and to assess remodeling effects, Dr. Lewis said.

        The double-blind, placebo-controlled study, presented here on September 11th at the Heart Failure Society of America 10th annual scientific meeting (HSFA), randomized 40 patients with New York Heart Association Class III or IV systolic HF and secondary pulmonary hypertension to receive either placebo or oral sildenafil, in doses of up to 50 mg 3 times daily, as tolerated, for 12 weeks.

        Study subjects were assessed at baseline and 12 weeks after the initial sildenafil dose, for right heart hemodynamics, gas exchange, neurohormonal levels and ventriculography.

        At the end of the study, the 14 patients on sildenafil not only demonstrated improved exercise capacity but also had fewer hospitalizations for HF -- 1 versus 7 in the placebo group.

        At completion of the study, all patients were eligible to receive open-label sildenafil.

        Sildenafil's safety profile in the HF patients appeared favorable, in that adverse events did not differ significantly between the 2 groups, according to the researchers.


        [Presentation title: Sildenafil Therapy for Systolic Heart Failure with Secondary Pulmonary Hypertension: A Randomized Double-Blind, Placebo-Controlled Study. Abstract 223]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send